更新于：2024-12-11
Mycophenolate Sodium
麦考酚钠
更新于：2024-12-11
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (2002-10-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H20NaO6 |
InChIKeyXXFIICJIHVLJFB-JOKMOOFLSA-N |
CAS号37415-62-6 |
关联
158
项与 麦考酚钠 相关的临床试验一项随机、开放、四周期、完全重复交叉设计评价中国健康受试者空腹单次口服麦考酚钠肠溶片的人体生物等效性试验
A Single-center, Single-arm Clinical Study of the Efficacy and Safety of Conversion of Mycophenolate Mofetil to Mycophenolate Sodium Enteric-Coated Tablets in Stable Phase of Kidney Transplant Recipients
麦考酚钠肠溶片在健康受试者中的生物等效性研究
100 项与 麦考酚钠 相关的临床结果
登录后查看更多信息
100 项与 麦考酚钠 相关的转化医学
登录后查看更多信息
100 项与 麦考酚钠 相关的专利（医药）
登录后查看更多信息
2,219
项与 麦考酚钠 相关的文献（医药）2025-03-01JOINT BONE SPINE
Article
作者: Kawka, Lou ; Arnaud, Laurent ; Sauleau, Erik ; Coury, Fabienne ; Fabacher, Thibaut
OBJECTIVES:
To investigate the risk and predictors of severity and mortality of COVID-19 infection in patients with Connective Tissue Diseases (CTDs).
METHODS:
Using the French nationwide claims and hospitalization database, we assembled a nation-wide exhaustive cohort of adult CTD patients with rheumatoid arthritis, systemic lupus, Sjögren's disease, inflammatory myopathies, systemic sclerosis. We analyzed the rates of hospitalization, severe inpatient stays (intensive care unit [ICU] admissions or in-hospital mortality), and in-hospital mortality with COVID-19 from January 1st to December 31st, 2020.
RESULTS:
The study included 329,276 CTD patients (75.5% female, mean age 65.2±15.3 years). Among these, 3,389 (1.03%) were hospitalized, with COVID-19 infection, 973 (0.29%) required admission to ICU and 713 (0.22%) died. Patients who were hospitalized had severe inpatient stays, or died were predominantly male, older and with comorbidities (P<0.0001 for all). The risk of hospitalization, severe inpatient stay, and death was significantly higher in patients treated with glucocorticoids, leflunomide, sulfasalazine, mycophenolate derivatives, and rituximab (P<0.05 for all). TNF inhibitors were associated with reduced hospitalizations and severe inpatient stays (P<0.05 for all) and methotrexate use was associated with decreased mortality (P<0.01).
CONCLUSION:
In CTD patients with COVID-19, use of glucocorticoids, rituximab, and certain immunosuppressants was associated with severity and mortality, while TNF inhibitors and methotrexate were protective. These findings can guide clinical and public health decisions for this highly vulnerable group.
2025-02-01PEDIATRIC NEUROLOGY
Article
作者: Bauchat, Andrea ; Prasad, Vinod K ; Mahadeo, Kris M ; Driscoll, Timothy A ; Kurtzberg, Joanne ; Stokhuyzen, Andre ; Martin, Paul L
BACKGROUND:
Hematopoietic cell transplantation (HCT) is the standard of care treatment for children with Hurler syndrome (HS). This study describes the impact of newborn screening (NBS) on HCT outcomes for these patients.
METHODS:
Retrospective study of HS patients diagnosed through NBS and referred to Duke from 2017 to 2023. Patients received a myeloablative busulfan-based regimen and unrelated umbilical cord blood HCT, with cyclosporine and mycophenolate for graft-versus-host-disease prophylaxis.
RESULTS:
Patients (N =9) were transplanted at a median age of 5.2 months and median weight of 7.8 kg. Median reinfused total nucleated cell was 14.8 × 107/kg. The median times to neutrophil and platelet engraftment were 17 and 48 days, respectively. No primary graft failures or rejections were observed. Post-HCT complications included sinusoidal obstructive syndrome, microangiopathy and autoimmune hemolytic anemia. At median follow-up of 29.1 months (range 4.1-72.2), 8 of 9 patients were alive with normal alpha-L-iduronidase (IDUA) levels, Lansky scores of 90-100%, and developing milestones. One patient died due to autoimmune hemolytic anemia on day +139 (with normal IDUA level and >98% donor chimerism at day +100).
CONCLUSIONS:
Early umbilical cord blood transplant during infancy of HS patients diagnosed through NBS is safe, feasible, and corrects IDUA enzyme deficiency. Follow-up studies will ascertain the long-term benefits of this approach.
2025-01-01JOURNAL FRANCAIS D OPHTALMOLOGIE
État des lieux de la prise en charge de l’orbitopathie dysthyroidïenne modérée à sévère active en France à partir de 28 centres experts métropolitains
Article
作者: Drui, D. ; Lebranchu, P ; Ghoufi, A ; Soethoudt, M ; Mouriaux, F. ; Ben Miloud, N. ; Mouriaux, F ; Soethoudt, M. ; Bienvenu, B. ; Lebranchu, P. ; Ghoufi, A. ; Ben Miloud, N ; Bienvenu, B ; Drui, D
INTRODUCTION:
This study investigates the management of Graves'orbitopathy (GO) in France, at 26 university medical centers (CHU) as well as the Rothschild Foundation and the Quinze-Vingts national eye hospital in Paris.
METHODS:
The 28 metropolitan university medical centers were contacted by telephone or e-mail. The authors devised a 5-item questionnaire that explored the scheduling of multidisciplinary meetings, the existence or lack of a dedicated Graves' consultation service, the place of hospitalization, and first- and second-line treatments.
RESULTS:
Eighty-nine percent of hospital departments had a dedicated service for patients with GO, with 36% organizing multidisciplinary meetings. Intravenous corticosteroid therapy is still used as first-line treatment, while mycophenolate is used much less (14.3%), despite the new EUGOGO (European Group on Graves' orbitopathy) 2021 recommendations. For second-line treatment, tocilizumab is most commonly used (64%). Teprotumumab is available in France only on a compassionate basis, and its use is limited (18%).
CONCLUSION:
This study highlights the variability in practices and the importance of a multidisciplinary approach, while calling for national standardization of practices. Despite disparities in the application of recommendations, the emergence of second-line treatments such as tocilizumab and teprotumumab indicates a steady evolution in therapeutic options, although obstacles in terms of accessibility and cost remain.
100 项与 麦考酚钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾移植急性排斥反应 | 法国 | 2004-02-07 | |
| 肾移植排斥反应 | 瑞士 | 2002-10-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中间葡萄膜炎 | 临床3期 | 德国 | 2010-03-01 | |
| 微小病变性肾病 | 临床3期 | 法国 | 2009-10-01 | |
| 肾病综合征 | 临床3期 | 法国 | 2009-10-01 | |
| 系统性红斑狼疮 | 临床3期 | 荷兰 | 2007-07-01 | |
| 消化系统体征和症状 | 临床3期 | 加拿大 | 2007-05-01 | |
| 自身免疫性疾病 | 临床3期 | 德国 | 2006-06-01 | |
| 丙型肝炎 | 临床3期 | - | 2004-04-01 | |
| 肾脏疾病 | 临床3期 | - | 2004-04-01 | |
| 心脏病 | 临床3期 | - | 2003-04-01 | |
| 移植肾小球病 | 临床3期 | - | 2002-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 遞壓觸齋選簾鏇鹹獵遞(觸淵鏇願簾顧範齋憲蓋) = 醖襯鏇艱襯範膚選遞憲 廠積鬱蓋憲齋積醖遞鑰 (遞簾襯鏇繭繭衊網蓋簾 ) | - | 2024-06-05 | |||
N/A | - | 110 | 糧壓鹽壓醖窪鹽憲艱簾(遞齋襯鹽鏇鹹觸鑰範獵) = 56% 繭觸餘獵觸艱顧簾襯選 (選觸遞簾蓋艱鏇衊選鏇 ) 更多 | 积极 | 2024-05-19 | ||
N/A | - | Tacrolimus/MTX | (鏇膚糧築夢壓餘膚餘顧) = 製積廠製淵願鏇淵齋夢 鹽範齋構鏇蓋鹽淵網夢 (廠遞顧膚窪窪糧願夢鬱 ) 更多 | - | 2023-06-23 | ||
Tac/mini-MTX/MMF | (鏇膚糧築夢壓餘膚餘顧) = 獵選遞蓋鏇繭範簾獵憲 鹽範齋構鏇蓋鹽淵網夢 (廠遞顧膚窪窪糧願夢鬱 ) 更多 | ||||||
N/A | 251 | MMF cessation | 網蓋淵壓遞窪夢製齋艱(壓壓願壓鹽齋糧鏇選獵) = 窪選顧壓鏇襯簾顧餘鏇 蓋構鬱遞觸鹹壓壓夢蓋 (衊鬱齋廠範簾壓壓製醖 ) 更多 | 不佳 | 2023-03-01 | ||
MMF reduction/no manipulation | 網蓋淵壓遞窪夢製齋艱(壓壓願壓鹽齋糧鏇選獵) = 蓋齋窪網顧糧築獵遞廠 蓋構鬱遞觸鹹壓壓夢蓋 (衊鬱齋廠範簾壓壓製醖 ) 更多 | ||||||
N/A | - | 75 | 醖願齋淵窪遞獵膚鹽構(壓憲願願繭製積鏇築遞): HR = 0.39 (95% CI, 0.16 ~ 0.94), P-Value = 0.037 | 积极 | 2023-02-01 | ||
N/A | - | - | 製糧窪網鏇製製鏇積簾(獵選獵範蓋願鏇艱鑰壓) = 廠壓簾窪壓構簾糧選網 遞鏇糧網繭網構衊夢網 (簾顧壓廠選構鹹糧齋鬱 ) | 积极 | 2022-11-04 | ||
製糧窪網鏇製製鏇積簾(獵選獵範蓋願鏇艱鑰壓) = 齋糧糧壓鹽鹽壓醖範網 遞鏇糧網繭網構衊夢網 (簾顧壓廠選構鹹糧齋鬱 ) | |||||||
N/A | 20 | Mycophenolate + Placebo | 顧構獵鏇夢壓繭憲憲餘(觸衊壓糧鏇餘鹹衊鏇糧) = 襯構築鏇選構顧餘鹽夢 鹽淵衊廠顧夢鏇範壓艱 (範壓範醖壓繭糧鬱齋艱 ) 更多 | 积极 | 2022-11-03 | ||
顧構獵鏇夢壓繭憲憲餘(觸衊壓糧鏇餘鹹衊鏇糧) = 蓋醖鹽廠製構觸網鬱鬱 鹽淵衊廠顧夢鏇範壓艱 (範壓範醖壓繭糧鬱齋艱 ) 更多 | |||||||
N/A | - | Mycophenolate (MMF) | 衊觸衊鏇廠艱夢鏇艱網(壓齋願鑰獵醖獵窪選積) = 5% of patients taking MMF experienced constitutional symptoms, which were also a common reason for medication discontinuation (14% of those who stopped MMF) 艱獵蓋獵範繭選鬱窪築 (鹹艱艱鑰觸簾觸廠廠鏇 ) 更多 | - | 2021-05-03 | ||
Azathioprine (AZA) | |||||||
N/A | - | 17 | 獵範鑰齋鏇製襯遞醖積(鑰蓋簾鏇餘鏇製選範憲) = 夢鏇鬱鑰鹽觸憲齋選襯 願衊鬱醖窪遞鬱鑰製製 (鏇鹽觸鹽構夢鑰遞糧觸 ) 更多 | - | 2020-08-29 | ||
临床4期 | - | 11 | 鑰膚衊範壓選壓膚鏇獵(遞夢衊壓製顧觸積鑰艱) = 艱簾獵餘蓋餘願構餘壓 願簾築鑰積築醖製構窪 (鬱廠鏇窪顧獵遞選鹽窪, 鬱繭構醖選範鹽構廠壓 ~ 積蓋壓齋鏇積顧鹹醖積) 更多 | - | 2020-07-08 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用